Interferon regulatory factor 4 as a context-dependent regulator of inflammation: transcriptional and epigenetic control, skin diseases, and translational challenges
Interferon regulatory factor 4 is defined as a context-encoded intracellular mediator only when reversible, context-resolved perturbation links target engagement to a prespecified molecular programme and disease-relevant phenotype.
Abstract
Inflammatory mediators are usually defined as extracellular signals, yet intracellular regulators determine which signals are converted into cell-specific, durable inflammatory programmes. Interferon regulatory factor 4 (IRF4) is a stringent test of this broader concept because its effects vary with abundance, partner choice, chromatin accessibility, metabolism, cell lineage, tissue, and disease phase. We conducted a systematised narrative review and applied a causal-discrimination framework that separates lineage determination and activation from downstream amplification, necessary mediation, sufficiency, and therapeutic tractability. Across immune compartments, IRF4 supports pathogenic T helper 17 and type 2 programmes but also maintains regulatory T cells, humoral immunity, antitumour CD8 T-cell activity, intestinal group 3 innate lymphoid cells, and skin repair. Psoriasis provides the most developed disease-linked preclinical hypothesis, although the evidence is concentrated in one 2025 study and shows pre-induction benefit in an acute mouse model rather than reversal of established human disease. Atopic dermatitis remains a candidate epithelial and immune-network context without independent target validation. Conflicting evidence on IRF4 dependence in differentiated T helper 17 cells further shows that developmental requirement cannot be assumed to predict acute therapeutic sensitivity. We therefore define IRF4 as a context-encoded intracellular mediator only when reversible, context-resolved perturbation links target engagement to a prespecified molecular programme and disease-relevant phenotype. Human-tissue perturbation, cell- and complex-resolved target engagement, lesional pharmacokinetics and pharmacodynamics, reversibility, incremental value over established pathway control, and exposure-matched safety testing are the decisive gates for translation.
Macrophageexhibit remarkable functional plasticity and adopt M1-like pro-inflammatory or M2-like anti-inflammatory/pro-resolving states in response to microenvironmental stimuli. Notably, this binary functional classification originates largely from in-vitro experimental systems; tissue-resident macrophages in vivo dis...
Shu-Qi Cao, Shuang Feng, Yue Gao et al.· Frontiers in Immunology· 0 citations
It is shown that STAT3 plays a context-dependent role in antiviral natural killer cells, either promoting or impairing adaptive responses depending on the inflammatory milieu during mouse cytomegalovirus infection.
S. Grassmann, Hyunu Kim, Timo Rückert et al.· Science immunology· 0 citations
Abstract Interferon regulatory factor 5 (IRF5) is a transcription factor at the nexus of immune regulation, inflammation, and autoimmune disease. Studies have shown that dysregulation of IRF5 is strongly implicated in the pathogenesis of autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthr...
Laura Menocal, Amanda Y. Y. Huang, Anjali Rachelkar et al.· Biochemical Society Transact...· 0 citations
It is demonstrated that Th17 development is shaped by a combination of signals, including TGF-β, extracellular lactate, and hypoxia, and mitochondrial activity is closely linked to Th17 differentiation.
Inflammatory signals are broadly conserved, yet how tissue context converts them into programs of recovery or maladaptive repair remains unclear. Using kidney injury as a model of inflammation-to-repair transitions, we identify an injury-induced proximal-tubule complement program in which cell-intrinsic complement prot...
Tilo Freiwald, Daniel Chauss, Md Tajmul et al.· bioRxiv· 0 citations
Prospective, compartment-resolved biomarker studies are needed to match agonists, delivery systems, combination regimens, or inhibitory approaches to the appropriate tumor state, and STING inhibition in chromosomal-instability-high tumors remains a promising preclinical hypothesis, not an established treatment.